![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
20
Sun Pharmaceutical Industries Limited Mumbai In, based in India, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their significant offerings is Candesartan cilexetil, supported by a 'Withdrawn by Holder' Certificate of Suitability (CEP) with the number R1-CEP 2012-110 - Rev 01
This Chemical Type CEP, issued on April 04, 2019, remains in force until January 06, 2022, ensuring its reliability within the pharmaceutical industry.
Substance Number 2573 associated with this CEP further emphasizes